Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT01722513
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 150 participants
- Registry
-
NCT01722513
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01722513. Allocation not applicable; single masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2013-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
- Condition
- Kidney Diseases
- Condition
- Diabetes Mellitus
- Condition
- Acute Kidney Injury
- Condition
- Kidney Failure, Chronic
- Condition
- Renal Insufficiency
- Intervention (Drug)
- Alprostadil ﹠control
- Lead sponsor
- Shanghai 10th People's Hospital
Record details
- Record id
cardio:ct-nct01722513- Content hash
2d8dc3bbd656b32e580c9bf97bfcfa07c9e3103a3565d5b44f7b7db391e659a6